布地奈德氧驱动雾化治疗COPD急性加重期的临床效果

Clinical effects of budesonide oxygen driving atomization on patients with chronic obstructive pulmonary disease at acute exacerbation phase

目的研究布地奈德氧驱动雾化治疗慢性阻塞性肺病(COPD)急性加重期的安全性与有效性。方法入选2007年3月～2011年9月在呼吸内科诊疗的COPD急性加重期患者123例,随机分成3组,每组41例,分别为布地奈德氧驱动雾化治疗组(B组)、甲基强的松静脉治疗组(M组)以及常规治疗对照组(C组)。比较治疗前后3组患者相关临床资料情况。结果 B组和M组治疗后的肺功能、血气情况及临床评分均较治疗前明显改善(P<0.05);治疗后,B组和M组的肺功能、血气情况及临床评分也均较C组明显改善(P<0.05)。B组与C组的不良反应发生率无统计学差异(P>0.05),而B组的不良反应发生率明显低于M组(P<0.05)。结论布地奈德氧驱动雾化可以取代甲强龙静脉治疗COPD急性加重期患者,具有较好的安全性与有效性。

Objective To study the safety and efficacy of budesonide oxygen driving atomization in the treatment of patients with chronic obstructive pulmonary disease（COPD） at acute exacerbation phase.Methods 123 patients with COPD at acute exacerbation phase who received treatment in our respiratory medical department from March 2007 to September 2011,were randomly divided into 3 groups with 41 ones in each group,i.e.budesonide oxygen driving atomization group（group B）,group receiving intravenous treatment with meprednisone（group M）,and control group receiving the conventional treatment（group C）.Comparison was made in the clinical data among three groups before and after the treatment.Results Compared with the situation before the treatment,the lung function,blood gas analysis,and clinical scores in group B and M were significantly improved（P0.05） after the treatment.These indexes in group B and C were significantly better than those in group C after the treatment（P0.05）.There was no significant difference in the incidence of adverse reaction between group B and C（P0.05）,but that incidence in group B was significantly lower than that in group M（P0.05）.Conclusion Budesonide oxygen driving atomization is of good safety and efficacy,which can displace the intravenous injection with meprednisone in the treatment of patients with COPD at acute exacerbation phase.